2-chloroadenosine has been researched along with Prostatic Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellezza, I; Minelli, A; Tucci, A | 1 |
| Bellezza, I; Conte, C; Culig, Z; Minelli, A; Rambotti, MG; Tucci, A | 1 |
| Agostini, M; Bellezza, I; Bracarda, S; Culig, Z; Minelli, A | 1 |
| Bellezza, I; Bracarda, S; Conte, C; Culig, Z; Minelli, A; Tucci, A | 1 |
1 review(s) available for 2-chloroadenosine and Prostatic Neoplasms
| Article | Year |
|---|---|
2-Chloroadenosine and human prostate cancer cells.
Topics: 2-Chloroadenosine; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Gene Expression; Humans; Interleukin-23; Male; Molecular Structure; Prostatic Neoplasms; Receptor, PAR-1 | 2008 |
3 other study(ies) available for 2-chloroadenosine and Prostatic Neoplasms
| Article | Year |
|---|---|
Differential involvement of reactive oxygen species and nucleoside transporters in cytotoxicity induced by two adenosine analogues in human prostate cancer cells.
Topics: 2-Chloroadenosine; Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Cladribine; Disease Models, Animal; Glutathione; Humans; Male; Mice; NF-E2-Related Factor 2; Nucleoside Transport Proteins; Prostatic Neoplasms; Purinergic P1 Receptor Agonists; Reactive Oxygen Species | 2009 |
Mechanism of 2-chloroadenosine toxicity to PC3 cell line.
Topics: 2-Chloroadenosine; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Damage; DNA, Neoplasm; Drug Screening Assays, Antitumor; Humans; Male; Prostatic Neoplasms | 2006 |
2-chloroadenosine modulates PAR-1 and IL-23 expression and enhances docetaxel effects on PC3 cells.
Topics: 2-Chloroadenosine; Agar; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Tumor; Docetaxel; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Interleukin-23 Subunit p19; Male; Prostatic Neoplasms; Receptor, PAR-1; S Phase; Stem Cells; Taxoids | 2008 |